A Phase 2 interventional study of Placebo and FP187 in Plaque Psoriasis, sponsored by Forward-Pharma GmbH. Completed at 2 sites in Germany. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2012-12-11.
Sponsored by Forward-Pharma GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 299 studies in Psoriasis with a site in Germany — 13 open to participants now, 30 under way, 15 of them phase 3. Psoriasis · Germany.
Among the 299 studies in Psoriasis with a site in Germany, this one is the 112th largest by enrollment of the 260 interventional ones that give a count, is one of 17 that started in 2010, is one of 74 in phase 2, and was the 67th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →13 of the 299 studies in Psoriasis with a site in Germany are open now. Recruiting first, the newest first:
Takeda · Sites in Germany, United States, China and 4 more countries
Ages 4–17
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 13 more countries
Ages 12–17
UCB Biopharma SRL · Sites in Germany, United States, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 22 more countries
Ages 40+
LEO Pharma · Sites in Germany, United States, Canada and 2 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
299 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 83 · Phase 3 122 · Phase 4 23
First in 2000; this study’s year is marked. 17 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 196 across the 260 interventional studies, 588 across the 39 observational. Of the 264 that completed or were terminated, 160 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
274 of 299 have an industry lead sponsor. The 10 most frequent:
Forward-Pharma GmbH is the lead sponsor of 2 studies on the registry; none are open to participants now.
Forward-Pharma GmbH has 2 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
2 of the studies in Psoriasis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013201LEO PharmaA 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis | 2027-06-04 |
| NCT03886246LEO PharmaEffisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 299 studies in Psoriasis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to investigate the efficacy and safety of different doses and dose administrations of FP187 compared to a placebo treatment in patients with moderate to severe plaque psoriasis.
The trial tests two different dose levels and two different daily dosing schedules (twice daily (BID) and three times daily (TID))over 20 weeks of treatment. Key is effect as measured by achievement of a 75% reduction in PASI after 20 weeks and safety monitored by adverse events and safety lab.
There are 3 active arms:
and 1 placebo arm.
An additional open (flexible dosing) treatment arm has been amended to the trial
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sexually active females of must be either surgically sterile (hysterectomy or tubal ligation) or use a highly effective (failure rate \< 1%) medically accepted method during the trial as well as one month after trial is finished such as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FP187 250mg TID (total daily dose of 750mg)
Drug: FP187
FP187 375mg BID (total daily dose of 750mg)of 750mg administered as 375mg BID
Drug: FP187
FP187 250mg BID (total daily dose of 500mg)
Drug: FP187
Placebo treatment
Drug: Placebo
Open treatment using a flexible dosing schedule for 8 weeks with maximum dose of 750mg FP187 and with a total dosing of 20 weeks. All investigations following same schedule.
Drug: FP187
Proportion of patients achieving PASI 75 compared to placebo
Proportion of patients achieving PASI75 (a reduction in the PASI score of 75% or more)
Time frame: After 20 weeks of treatment
PASI 75
Proportion of patients achieving PASI75 (a reduction of the PASI score of 75% or more compared to baseline)
Time frame: At week 4, 8, 12 and 16
PASI 50
Proportion of patients who achieves PASI 50 (a reduction of the PASI score of 50% or more compared to baseline)
Time frame: At week 4, 8, 12, 16 and 20
PASI 90
Proportion of patients achieving PASI90 (a reduction of the PASI score of 90% or more compared to baseline
Time frame: At week 4, 8, 12, 16 and 20
PGA (Physicians Global Assessment)
On a 5-point scale from 0 (abscence or very mild disease) to 4 (very severe disease) proportion of patients being responders - defined as patients achieving either a score of 0 or 1 or a two point improvement
Time frame: At week 4, 8, 12, 16 and 20
PaGA (Patients Global Assessment
Patients evaluation on a 5-point Likert scale 1 (very good) - 5 (very poor)based on the evaluation of: "Considering all the ways your psoriasis affects you, how have you been doing in the last 24 hours?"
Time frame: At week 4,8,12,16 and 20
Pruritus
Patient evaluation of pruritus measured on a VAS (Visual Analog Scale) from 0mm (no pruritus) to 100mm (worst possible pruritus)
Time frame: At week 4, 8, 12, 16 and 20
Patient rated QoL (Quality of Life)
Patient filling in 10 questions on the DLQI QoL system with a calculated summary score and analysis of the improvement from baseline
Time frame: At week 4, 8, 12, 16 and 20
Adverse events (AEs)
Summary of incidense and severity of AEs and ADRs (Adverse Drug Reactions)/SAEs (Serious Adverse Events)/SUSARs (Suspected Unexpected Serious Adverse Reactions)
Time frame: At week 4, 8, 12, 16 and 20
Safety lab test
Summary of lab parameters and clinically relevant changes over the treatment period in standard clinical chemistry tests, standard haematology tests and urin dip stick test
Time frame: At week 20
The record gives a start of Sep 2010, a primary completion of Jan 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate
Forward-Pharma GmbH